Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 393 - 400 of 12007 results

Continuation Funds: Top 5 Considerations
December 20, 2024| Blog| Viewpoint

US Department of Homeland Security Publishes H-1B Modernization Rule
December 20, 2024| Alert| Viewpoint

DHS Publishes Final Rule Authorizing Automatic EAD Extensions
December 19, 2024| News

Congress Passes Defense Bill with AI Provisions — AI: The Washington Report
December 19, 2024| Article| Viewpoint

USPTO Takes a Hint from European Practice in Addressing Late Continuation Concerns
December 19, 2024| Blog| Viewpoint

Canada’s Fall Economic Statement: A Silver Lining for Innovators Amidst the Chaos
December 18, 2024| Alert| Viewpoint

Preparation for 2024 Fiscal Year-End SEC Filings and 2025 Annual Shareholder Meetings
December 17, 2024| Advisory| Viewpoint

Mintz on Air: Predictions and Practical Policies – Workplace Whiplash
December 17, 2024| Podcast| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|

Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|
